Iradimed Co (IRMD)

Healthcare Medical Devices

90.90 $

-4.6% vs. previous close

Closing price · As of: 31. Jul 2026

Add to watchlist

Stock Watch

Stock Watch will tell you what changes at Iradimed Co.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 5 of our scanner strategies — each hit links to the scanner.

Quality & Balance Sheet

Pros 80%

Momentum & Trend

Above 21-EMA Pullback Above the 50- & 200-SMA Power Trend Stan Weinstein: Stage 1

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Basics

Market Cap

1.2$B

Shares Outstanding

13Mio.

Float

65.1%

Beta

0.9

Performance

Perf. 1M

2.00%

Perf. 3M

-3.20%

Perf. 6M

-2.70%

YTD Performance (%)

-4.70%

52-Week-High Distance

-13.0%

Perf. 1Y

61.32%

Perf. 3Y

103.60%

Perf. 5Y

265.53%

Valuation

P/E

–

Forward P/E

41.2

PEG

4.5

P/B

–

P/S

13.4

EV/EBITDA

42.2

Price/FCF

46.9

Profitability

Gross Margin

76.8%

EBIT Margin

–

Net Margin

27.4%

Return on Equity

25.0%

Return on Assets

16.2%

Balance Sheet & Safety

Equity Ratio

–

Debt/Equity

–

fortress balance sheet

Altman Z″

17.72

Piotroski

6 out of 9

Growth

Sales Growth Last Quarter

12.60%

EPS Growth Last Quarter

22.10%

Sales Growth (Year)

14.43%

Forward Sales Growth

10.64%

Forward EPS Growth

13.50%

Dividend

Dividend Yield

0.79%

Dividend Per Share (TTM)

1.24$

Payout Ratio

54.9%

Years Without a Cut

1Years

Increase Streak

1Years

Quality & Screener

Stage

RS Rating

EPS Rating

Piotroski

6 out of 9

Fundamental Rating

B (60 out of 100)

fortress balance sheet

Altman Z″

17.72

AI Rating

–

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 90.90 $

Price Target (average) 118.00 $

The price target sits 29.8% above the current price.

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Next Reporting Date

7. Aug 2026

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

From To Indexed

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter	EPS (Earnings Per Share)	EPS YoY (%)	Sales ($M)	Sales YoY (%)	Net Margin (%)	OCF ($M)	FCF ($M)
2024: Q4	0.40	13.00	19	11.10	26.50	6	3
2025: Q1	0.37	12.60	20	10.90	24.00	4	1
2025: Q2	0.45	17.20	20	13.80	28.30	8	5
2025: Q3	0.43	9.80	21	15.70	26.30	7	6
2025: Q4	0.50	24.30	23	17.00	28.40	6	5
2026: Q1	0.45	23.70	22	12.60	26.50	8	8
2026: Q2	0.41	-8.90	21	0.50	25.40	6	6

What Do These Terms Mean?

EPS (Earnings Per Share):: Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):: Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:: All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:: What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):: The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):: Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

IRADIMED CORPORATION entwickelt, fertigt, vermarktet und vertreibt MRT-kompatible intravenöse Infusionspumpensysteme sowie MRT-kompatible Patientenvitalwert-Überwachungssysteme und zugehöriges Zubehör. Das Unternehmen bietet MRidium 3870 und 3860+ MRT-kompatible IV-Infus…

CEO Insider Trades (12 Mo.)	selling own stock
Employees	166
Headquarters	Orlando, FL
Website	iradimed.com
IPO Date	16. Jul 2014

Management

Management
Name	Title	Birth Year
Roger E. Susi	Founder, Chairman, CEO & President	1953
John F. Glenn	CFO & Corporate Secretary	1962
Jeff Chiprin	Chief Commercial Officer	1966
Randy Waddell	Vice President of Worldwide Sales & Marketing	–
Chris Williamson	Executive Vice President of Continuous Improvement & Information Technology	–
Matt Garner	Controller	–
Lynn Neuhardt	Vice President of Research & Development	–

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Insider Transactions

Insider Transactions
Date	Person	Role	Type	Shares	Price	Value
21. Apr 2026	Roger E Susi	CEO	Sell	2,500	90.94	227,350
20. Apr 2026	Roger E Susi	CEO	Sell	5,000	93.36	466,800

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.